Positive 5-year data argue for early identification and treatment of symptomatic patients in whom transcatheter edge-to-edge repair is appropriate for heart failure with secondary mitral regurgitation.
PRIMARY Trial Aims to Guide Choice of Percutaneous Vs. Surgical Repair of Degenerative Mitral Regurgitation
The new NIH-funded multicenter investigation will help determine which therapy — MitraClip or surgery — is better in which patient types.
No. 2 Medical Innovation for 2020: Expanded Use of Minimally Invasive Mitral Valve Surgery
Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
MitraClip Drives Down Deaths, HF Hospitalization in Secondary Mitral Regurgitation
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Managing Mitral Valve Disease in 2016
Robotic and catheter-based techniques promise to make mitral valve repair and replacement less invasive than ever. But how effective are they, and are robotic approaches ready to go mainstream?
Transcatheter Valve Procedures Gain Steam with More Populations, New Applications
There’s no end in sight to the past decade of progress in transcatheter aortic valve replacement (TAVR). But experts say the coming years may prove to be the decade of TMVR, or transcatheter mitral valve replacement.
MitraClip Reaches Real-World Use in U.S., but Population Refinement Remains
This newly approved percutaneous therapy offers a minimally invasive option for mitral regurgitation patients at high risk from surgery. Ongoing studies aim to better define just which patients benefit.